论文部分内容阅读
慢性阻塞性肺疾病(COPD)患者因症状明显就诊时其肺功能往往已有相当程度受损,肺量计的应用实现了早期诊断和治疗COPD的可能。第一秒用力呼气容积(FEV1)在COPD的诊断、治疗、预后评价等方面发挥着不可或缺的作用。但COPD是一系统性疾病,除肺功能进行性衰减外,尚有许多肺外表现,如系统性炎症、体重下降、肌肉质量减少和功能不良以及对心血管系统、神经系统的影响等。因此,单一的.FEV1对COPD患者的健康状况、生活质量、治疗反应和预后等并不能作出较精确的评估。本文将对FEV1在COPD中的应用及其局限性作一概述。
Chronic obstructive pulmonary disease (COPD) patients often have significant damage to their lung function due to obvious symptoms, and the use of spirometers enables the early diagnosis and treatment of COPD. The first second forced expiratory volume (FEV1) plays an indispensable role in the diagnosis, treatment and prognosis of COPD. However, COPD is a systemic disease. In addition to progressive attenuation of pulmonary function, there are many extra-pulmonary manifestations such as systemic inflammation, weight loss, decreased muscle mass and dysfunction, as well as cardiovascular and neurological effects. Therefore, a single .FEV1 does not provide a more accurate assessment of COPD patients’ health, quality of life, treatment response, and prognosis. This article will FEV1 in the application of COPD and its limitations are summarized.